BIOSYNTH SRL has a total of 50 patent applications. Its first patent ever was published in 1992. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, environmental technology and biotechnology are OPHIREX INC, MACREGEN INC and SL VAXIGEN INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 12 | |
#2 | EPO (European Patent Office) | 6 | |
#3 | WIPO (World Intellectual Property Organization) | 6 | |
#4 | Australia | 5 | |
#5 | Canada | 5 | |
#6 | Italy | 3 | |
#7 | China | 2 | |
#8 | EAPO (Eurasian Patent Organization) | 2 | |
#9 | Hungary | 2 | |
#10 | Singapore | 2 | |
#11 | Argentina | 1 | |
#12 | Hong Kong | 1 | |
#13 | Republic of Korea | 1 | |
#14 | New Zealand | 1 | |
#15 | Taiwan | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Environmental technology | |
#3 | Biotechnology | |
#4 | Macromolecular chemistry and polymers | |
#5 | Medical technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Climate change adaptation technologies | |
#4 | Peptides | |
#5 | Polysaccharides | |
#6 | Syringes |
# | Name | Total Patents |
---|---|---|
#1 | Porro Massimo | 47 |
#2 | Varra Martti | 3 |
#3 | Tommasi Franco | 1 |
#4 | Masi Mauro | 1 |
#5 | Porro Massimo M | 1 |
Publication | Filing date | Title |
---|---|---|
US2017209563A1 | Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria | |
ITMI20130142A1 | GLYCOCOUGUGAR VACCINES INCLUDING BASIC UNITS OF AN EXPRIMENT MOLECULAR CONSTRUCTED MULTIPLE EPITHOPES INCORPORATED | |
AU2002368447A1 | Broad-spectrum lps based vaccines of unencapsulated strains ofhaemophilus influenzae and other pathogenic species of gram-negative bacteria | |
US6951652B2 | Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases | |
EP0842666A2 | Combined use of anti-endotoxin synthetic peptides and of anti-endotoxin antibodies for the prophylaxis and treatment of endotoxicosis and septic shock | |
US5834430A | Potentiation of antibiotics | |
US5652211A | Peptides for neutralizing the toxicity of Lipid A | |
US5371186A | Synthetic peptides for detoxification of bacterial endotoxins and for the prevention and treatment of septic shock |